RSS feed (help and list of feeds)

Peer-Reviewed Articles

This page lists articles and letters prepared or contributed to by PHARMAC for publication in peer-reviewed journals and resources.

2009-2010

• New Zealand in fact has no cost-effectiveness threshold. Metcalfe S and Grocott R. International Journal of Environmental Research and Public Health, 7(4), 2010. (Comments on “Simoens, S. Health Economic Assessment: A Methodological Primer. Int. J. Environ. Res. Pub. Health 2009, 6, 2950-2966”).
• Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience. Grocott R. Expert Review of Pharmacoeconomics & Outcomes Research, 2009.

2007-2008

• Trastuzumab: Possible publication bias. Metcalfe S, Burgess C, Laking G, Evans J, Wells S and Crausaz S. The Lancet, 2008. (Further details for this article are in the authors' manuscript, available here (8 pages, 137 KB)).
• Funding a clinical trial: The perspective of a medicines funder. Alsop P, Metcalfe S and Evans J. Pharmacoeconomics, 2008.
• Trastuzumab: Possible publication bias. Metcalfe S, Burgess C, Laking G, Evans J, Wells S and Crausaz S. The Lancet, 17 May 2008.
• PHARMAC and cardiovascular health in New Zealand. Moodie P. NZ Medical Journal, 2008.
• Ciproxin HC eardrops application for funding—and response from PHARMAC. Baber WJ, Neeff M and Moodie P. NZ Medical Journal, 2008.
• Balancing the risks and benefits of celecoxib. Caldwell B, Beasley R, Weatherall M and Metcalfe S. American Journal of Medicine, 2007.
• PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER-2 positive early breast cancer. Metcalfe S, Evans J and Priest G. NZ Medical Journal, 2007.
• Medicines funding: Value for money is nothing new. Brougham M. British Medical Journal, 2007.
• PHARMAC responds on Herceptin assumptions and decisions. Metcalfe S and Evans J. NZ Medical Journal, 2007.
• PHARMAC and statins—correction is needed. Metcalfe S and Moodie P. NZ Medical Journal, 2007.
• PHARMAC’s updated guidelines for cost-effectiveness analyses, with new discount rate. Grocott R and Metcalfe S. NZ Medical Journal, 2007.
• Dealing with opportunity cost: A New Zealand perspective on trastuzumab funding. Metcalfe S, Crausaz S, Evans J and Brougham M. E-letter published in British Medical Journal, 2007.

2005-2006

• PHARMAC and erythropoietin for cancer patients. Grocott R, Metcalfe S and Moodie P. NZ Medical Journal, 2006.
• PHARMAC and EpiPen for anaphylaxis. Moodie P, Metcalfe S and Dougherty S. NZ Medical Journal, 2006.
• PHARMAC responds on agents to prevent osteoporotic fractures. Metcalfe S, Wilkinson T and Rasiah D. NZ Medical Journal, 2006.
• More on PHARMAC and tobacco control in New Zealand. Metcalfe S and Moodie P. NZ Medical Journal, 2006.
• PHARMAC and statins—getting the best population health gains. Moodie P, Dougherty S and Metcalfe S. NZ Medical Journal, 2006.
• PHARMAC responds on tolterodine for overactive bladder. Moodie P. NZ Medical Journal, 2006.
• PHARMAC’s response on clopidogrel. Moodie P and Dougherty S. NZ Medical Journal, 2006.
• PHARMAC seeks clinical feedback on its cost-utility analysis methodology. Grocott R and Moodie P. NZ Medical Journal, 2006.
• More from PHARMAC on long-acting insulin analogues: Insulin glargine now funded. Moodie P. NZ Medical Journal, 2006.
• More from PHARMAC on temozolomide: Feedback needed. Rasiah D. NZ Medical Journal, 2006.
• Going against the flow: The impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. Grocott R and Metcalfe S. NZ Medical Journal, 2005.
• PHARMAC’s response on temozolomide and funding costly medicines that prolong life shortly. Metcalfe S, Crausaz S, Moodie P and McNee W. NZ Medical Journal, 2005.
• PHARMAC responds on treatments for pulmonary arterial hypertension. Metcalfe S, Rasiah D and Dougherty S. NZ Medical Journal, 2005.
• PHARMAC responds on TNF inhibitors for inflammatory arthritis. Metcalfe S, Moodie P, Grocott R and Wilkinson T. NZ Medical Journal, 2005.
• PHARMAC responds on long-acting inhalers for COPD. Metcalfe S and Dougherty S. NZ Medical Journal, 2005.
• PHARMAC responds on long-acting insulin analogues. Metcalfe S, Evans J and Moodie P. NZ Medical Journal, 2005.
• PHARMAC responds on salbutamol. Metcalfe S, Moodie P, Davies A, McNee W and Dougherty S. NZ Medical Journal, 2005.
• PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. Davies A, Metcalfe S, Moodie P and McNee W. NZ Medical Journal, 2005.
• PHARMAC and tobacco control in New Zealand: Two licensed funded options are already available. (with responses by Holt et al and the Editor). Metcalfe S, Moodie P and McNee W. NZ Medical Journal, 2005.
• PHARMAC responds to Richard Milne on discounting health benefits and costs. Metcalfe S, Brougham M, Moodie P and Grocott R. NZ Medical Journal, 2005.
• PHARMAC welcomes debate. Moodie P, McNee W and Metcalfe S. NZ Medical Journal, 2005.
• PHARMAC responds to the RMI’s editorial. Moodie P and McNee W. NZ Medical Journal, 2005.
• PHARMAC’s response to Tim Blackmore on the sole supply of influenza vaccine. McNee W, Moodie P, Schmitt S and Dick A. NZ Medical Journal, 2005.
• Response to ‘Exceptional circumstances and heart transplantation’ letter. Tomlinson P and Moodie P. NZ Medical Journal, 2005.

2002-2004

• Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices. (2 pages, 26 KB) Metcalfe S and Moodie P. Journal of Allergy & Clinical Immunology, 2004.
• Specific oral contraceptive use and venous thromboembolism resulting in hospital admission. Heuser P, Tonga K, Hopkins R, Henderson M, Weatherall M, Metcalfe S and Beasley R. NZ Medical Journal, 2004.
• Statin usage in Australia and New Zealand, and problems with use of DDDs. Metcalfe S and Moodie P. E-letter published in British Medical Journal, 2004.
• PHARMAC measures savings elsewhere to the health sector. Metcalfe S, Dougherty S, Brougham M and Moodie P. NZ Medical Journal, 2003.
• More on DTCA and the cost of asthma inhalers. McNee W. NZ Medical Journal, 2003.
• Direct-to-consumer advertising - Yes it can compromise patient health. Metcalfe S, McNee W and Moodie P. NZ Medical Journal, 2003.
• Response from PHARMAC: Difficult choices. Moodie P, Metcalfe S and McNee W. NZ Medical Journal, 2003.
• Death of pharmacy or safer dispensing? McNee W. NZ Medical Journal, 2003.
• More about cardiovascular disease and lipid management in New Zealand. Metcalfe S and Moodie P. NZ Medical Journal, 2002.
• Old letters, new rules. (1 page, 46 KB) Metcalfe S. The Lancet, 2002.
• Heart Protection Study. (1 page, 46 KB) Metcalfe S, Dawson S and Milne RJ. The Lancet, 2002.
• Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis: Celecoxib's relative gastrointestinal safety is overstated. Metcalfe S, Dougherty S and McNee W. British Medical Journal, 2002.

1997-2001

• Are drugs interchangeable? (2 pages, 57 KB) McNee W, Moodie P and Metcalfe S. The Lancet, 2000.
• PHARMAC at what cost? Moodie P and McNee W. New Zealand Medical Journal, 2000.
• Managing pharmaceutical expenditure while increasing access: The Pharmaceutical Management Agency (PHARMAC) experience. Braae R, McNee W and Moore D. Pharmacoeconomics, 1999.
• Statins and PHARMAC. McNee W and Smart T. New Zealand Medical Journal, 1998.
• PHARMAC and statins. Bennett W and McNee W. New Zealand Medical Journal, 1998.
• PHARMAC and flutamide. Bennett W. New Zealand Medical Journal, 1998.
• Statins. Bennett W. New Zealand Medical Journal, 1998.
• Use of statins In New Zealand: Subsidy of statins is limited to particular groups of patients. Bennett W, McNee W, Metcalfe S and Wright JM. British Medical Journal, 1997.
• Fluvastatin. Bennett W. New Zealand Medical Journal, 1997.

Page updated on 14 Jun 2010

Linked documents

Lancet Herceptin publication bias article (8 pages, 137 KB)

text

Seretide meta-analysis comment (2 pages, 26 KB)
Correspondence Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices To the Editor: The recent meta-analysis comparing Seretide fixed combination long-acting β-agonist/inhaled corticosteroid devices (LABA/ICSs) with concurrent salmeterol and fluticasone inhalers1 has important limitations in its…

text

Old letters, new rules (1 page, 46 KB)
CORRESPONDENCE Although a change to expedite publication of correspondence is welcome, we feel that reducing the time allowed for submission of letters from 8 to 2 weeks might be too short. This reduction could deter or prevent important correspondences to…

text

Heart Protection Study (1 page, 46 KB)
CORRESPONDENCE Although a change to expedite publication of correspondence is welcome, we feel that reducing the time allowed for submission of letters from 8 to 2 weeks might be too short. This reduction could deter or prevent important correspondences to…

text

Are drugs interchangeable? (2 pages, 57 KB)
CORRESPONDENCE The patient had a sibling who was mismatched for one HLA-haplotype and was able to provide bone-marrow stem cells instead of the matched unrelated donor. Natural rubber latex, the sap of the Brazilian rubber tree, is used to produce…

text